Press Releases April 14, 2026 08:00 PM

Beyond Air to Participate in the D. Boral Capital Global Conference 2026

Beyond Air to present at D. Boral Capital Global Conference 2026 with management one-on-one meetings

By Jordan Park XAIR
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
XAIR

Beyond Air, Inc., a NASDAQ-listed commercial-stage medical device and biopharmaceutical company specializing in nitric oxide therapies, announced that its CEO and CFO will participate in the D. Boral Capital Global Conference on May 7, 2026. The company highlights its LungFit PH system, FDA and CE approved for treating neonates with hypoxic respiratory failure, and underscores growth and market adoption plans amid inherent business risks.

Key Points

  • Beyond Air's CEO and CFO will engage in one-on-one meetings at the D. Boral Capital Global Conference to discuss company strategy and growth.
  • The company is focused on commercializing LungFit PH, a nitric oxide system for neonatal respiratory failure treatment, with FDA and CE approvals.
  • Forward-looking statements highlight plans for market expansion and commercial adoption but note inherent risks and uncertainties.

GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients’ lives, today announced that Robert Goodman, Chief Executive Officer, and Dan Moorhead, Chief Financial Officer of Beyond Air, will participate in the D. Boral Capital Global Conference 2026, which is being held on Thursday, May 7th, at The Plaza Hotel in New York.

Conference  Format: One-on-one meetingsConference Dates: May 7thParticipants: Robert Goodman, CEO, and Dan Moorhead, CFO of Beyond Air   

If you are interested in requesting a one-on-one meeting at the conference, please contact your D. Boral Capital representative to schedule accordingly.

About Beyond Air, Inc.

Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company’s expectations related to the commercial growth, market adoption of LungFit PH, expansion in the U.S. and international markets, and the Company’s long-term strategic and financial performance. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “potential,” “will,” “would,” “could,” “may,” and similar expressions, or by the use of future tense. These statements are based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management.

Because forward-looking statements relate to future events, they are subject to inherent risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s ability to successfully execute its commercial strategy, achieve market adoption of its products, maintain and expand customer relationships, manage leadership transitions effectively, obtain additional financing, and other risks described in the “Risk Factors” section of Beyond Air, Inc.’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission.

CONTACTS:

Investor Relations contact

Corey Davis, Ph.D.
LifeSci Advisors, LLC
[email protected]
(212) 915-2577


Risks

  • Potential challenges in successfully executing commercial strategy and achieving broad market adoption of LungFit PH.
  • Risks related to maintaining and expanding customer relationships and managing leadership transitions.
  • Dependence on obtaining additional financing and other operational risks outlined in the company's SEC filings.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026